Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males With Duchenne Muscular Dystrophy (DMD)

NCT05693142 is registered in ClinicalTrials.gov with REGENXBIO Inc. as lead sponsor.

NCT NCT05693142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05693142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
REGENXBIO Inc.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
January 4, 2023
Completion date
June 30, 2028
Enrollment
65 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy